Brookstone Capital Management
UTHR icon

Brookstone Capital Management’s United Therapeutics UTHR Stock Holding History

Brookstone Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.38M Buy
6,238
+294
+5% +$152K 0.03% 392
2026
Q2 		$3.22M Buy
5,944
+1,473
+33% +$830K 0.03% 399
2026
Q1 		$2.65M Sell
4,471
-2,151
-32% -$1.07M 0.03% 413
2025
Q4 		$3.23M Buy
6,622
+1,342
+25% +$625K 0.04% 370
2025
Q3 		$2.21M Buy
5,280
+349
+7% +$117K 0.03% 424
2025
Q2 		$1.42M Buy
4,931
+133
+3% +$39.7K 0.02% 488
2025
Q1 		$1.48M Buy
+4,798
New +$1.64M 0.02% 459

Other funds holding UTHR

Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Brookstone Capital Management's UTHR Position: Q3 2026 in Review

Brookstone Capital Management increased its United Therapeutics (UTHR) stake by 4.9% in Q3 2026, buying an estimated $152K and bringing the position to 6,238 shares worth $3.38M. The position accounts for 0.03% of the portfolio, ranked #392.

Brookstone Capital Management first reported a position in UTHR in Q1 2025 and has held it in 7 quarters since. 477 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Brookstone Capital Management held 6,238 shares of United Therapeutics worth $3.38M as of Q3 2026.
  • Brookstone Capital Management bought 294 United Therapeutics shares in Q3 2026, an estimated $152K.
  • United Therapeutics made up 0.03% of Brookstone Capital Management's portfolio in Q3 2026, its #392 holding.
  • Brookstone Capital Management first reported a position in United Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • 477 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Brookstone Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.